{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:35:49Z","timestamp":1785576949046,"version":"3.56.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,7,18]],"date-time":"2008-07-18T00:00:00Z","timestamp":1216339200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The occurrence of tuberculosis (TB), human immunodeficiency virus (HIV), and viral hepatitis infections in the same patient poses unique clinical and public health challenges, because medications to treat TB and HIV are hepatotoxic. We conducted an observational study to evaluate risk factors for HBsAg and\/or anti-HCV reactivity and to assess differences in adverse events and TB treatment outcomes among HIV-infected TB patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients were evaluated at the beginning, during, and at the end of TB treatment. Blood samples were tested for aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (BR), complete blood count, and CD4+ T lymphocyte cell count. TB treatment outcomes were assessed at the end of TB treatment according to international guidelines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of 769 enrolled patients, 752 (98%) had serologic testing performed for viral hepatitis: 70 (9%) were reactive for HBsAg, 237 (31%) for anti-HCV, and 472 (63%) non-reactive for both markers. At the beginning of TB treatment, 18 (26%) patients with HBsAg reactivity had elevated liver function tests compared with 69 (15%) patients non-reactive to any viral marker (p = 0.02). At the end of TB treatment, 493 (64%) were successfully treated. Factors independently associated with HBsAg reactivity included being a man who had sex with men (adjusted odds ratio [AOR], 2.1; 95% confidence interval [CI], 1.1\u20134.3) and having low TB knowledge (AOR, 1.8; CI, 1.0\u20133.0). Factors most strongly associated with anti-HCV reactivity were having injection drug use history (AOR, 12.8; CI, 7.0\u201323.2) and living in Bangkok (AOR, 15.8; CI, 9.4\u201326.5). The rate of clinical hepatitis and death during TB treatment was similar in patients HBsAg reactive, anti-HCV reactive, both HBsAg and anti-HCV reactive, and non-reactive to any viral marker.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Among HIV-infected TB patients living in Thailand, markers of viral hepatitis infection, particularly hepatitis C virus infection, were common and strongly associated with known behavioral risk factors. Viral hepatitis infection markers were not strongly associated with death or the development of clinical hepatitis during TB treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2458-8-245","type":"journal-article","created":{"date-parts":[[2008,7,18]],"date-time":"2008-07-18T18:15:01Z","timestamp":1216404901000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Viral hepatitis and HIV-associated tuberculosis: Risk factors and TB treatment outcomes in Thailand"],"prefix":"10.1186","volume":"8","author":[{"given":"Chawin","family":"Sirinak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanitchaya","family":"Kittikraisak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duangporn","family":"Pinjeesekikul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pricha","family":"Charusuntonsri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phinai","family":"Luanloed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"La-ong","family":"Srisuwanvilai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriprapa","family":"Nateniyom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somsak","family":"Akksilp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirirat","family":"Likanonsakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanchai","family":"Sattayawuthipong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Channawong","family":"Burapat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay K","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,7,18]]},"reference":[{"key":"1215_CR1","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1086\/518657","volume":"196 Suppl 1","author":"PC Onyebujoh","year":"2007","unstructured":"Onyebujoh PC, Ribeiro I, Whalen CC: Treatment options for HIV-associated tuberculosis. J Infect Dis. 2007, 196 Suppl 1: S35-5. 10.1086\/518657.","journal-title":"J Infect Dis"},{"key":"1215_CR2","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","volume":"167","author":"D Yee","year":"2003","unstructured":"Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D: Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003, 167: 1472-1477. 10.1164\/rccm.200206-626OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"1215_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00002030-200201040-00010","volume":"16","author":"GL Dean","year":"2002","unstructured":"Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, Fisher M, Taylor GP, Miller R, Taylor CB, de Ruiter A, Pozniak AL: Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS. 2002, 16: 75-83. 10.1097\/00002030-200201040-00010.","journal-title":"AIDS"},{"key":"1215_CR4","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.cld.2007.06.008","volume":"11","author":"MK Jain","year":"2007","unstructured":"Jain MK: Drug-induced liver injury associated with HIV medications. Clin Liver Dis. 2007, 11: 615-639. 10.1016\/j.cld.2007.06.008.","journal-title":"Clin Liver Dis"},{"key":"1215_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1097\/QAI.0b013e318032bbee","volume":"44","author":"L Jamisse","year":"2007","unstructured":"Jamisse L, Balkus J, Hitti J, Gloyd S, Manuel R, Osman N, Djedje M, Farquhar C: Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens. J Acquir Immune Defic Syndr. 2007, 44: 371-376. 10.1097\/QAI.0b013e318032bbee.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1215_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/01.aids.0000199014.66139.39","volume":"20","author":"G Breton","year":"2006","unstructured":"Breton G, Adle-Biassette H, Therby A, Ramanoelina J, Choudat L, Bissuel F, Huerre M, Dromer F, Dupont B, Lortholary O: Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis. AIDS. 2006, 20: 119-121. 10.1097\/01.aids.0000199014.66139.39.","journal-title":"AIDS"},{"key":"1215_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/00042560-200206010-00013","volume":"30","author":"DJ Hu","year":"2002","unstructured":"Hu DJ, Subbarao S, Vanichseni S, Mock PA, van Griensven F, Nelson R, Nguyen L, Kitayaporn D, Young NL, Des Jarlais D, Byers RJ, Choopanya K, Mastro TD: Higher viral loads and other risk factors associated with HIV-1 seroconversion during a period of high incidence among injection drug users in Bangkok. J Acquir Immune Defic Syndr. 2002, 30: 240-247.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1215_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S1473-3099(06)70685-5","volume":"7","author":"K Dolan","year":"2007","unstructured":"Dolan K, Kite B, Black E, Aceijas C, Stimson GV, Reference Group on HIV\/AIDS Prevention and Care among Injecting Drug Users in Developing and Transitional Countries: HIV in prison in low-income and middle-income countries. Lancet Infect Dis. 2007, 7: 32-41. 10.1016\/S1473-3099(06)70685-5.","journal-title":"Lancet Infect Dis"},{"key":"1215_CR9","unstructured":"Drug injection and HIV\/AIDS in Asia. [http:\/\/www.mapnetwork.org\/docs\/MAP_IDU%20Book%2024Jun05_en.pdf]"},{"key":"1215_CR10","first-page":"92","volume":"52","author":"C Padmapriyadarsini","year":"2006","unstructured":"Padmapriyadarsini C, Chandrabose J, Victor L, Hanna LE, Arunkumar N, Swaminathan S: Hepatitis B or hepatitis C co-infection in individuals infected with human immunodeficiency virus and effect of anti-tuberculosis drugs on liver function. J Postgrad Med. 2006, 52: 92-96.","journal-title":"J Postgrad Med"},{"issue":"6 Pt 1","key":"1215_CR11","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1164\/ajrccm.157.6.9711039","volume":"157","author":"JR Ungo","year":"1998","unstructured":"Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, Pitchenik AE: Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998, 157 (6 Pt 1): 1871-1876.","journal-title":"Am J Respir Crit Care Med"},{"key":"1215_CR12","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/ije\/dyl257","volume":"36","author":"K Hill","year":"2006","unstructured":"Hill K, Vapattanawong P, Prasartkul P, Porapakkham Y, Lim SS, Lopez AD: Epidemiologic transition interrupted: a reassessment of mortality trends in Thailand, 1980-2000. Int J Epidemiol. 2006, 36: 374-384. 10.1093\/ije\/dyl257.","journal-title":"Int J Epidemiol"},{"key":"1215_CR13","volume-title":"Global tuberculosis control: surveillance, planning, financing. WHO report 2007.","author":"World Health Organization","year":"2007","unstructured":"World Health Organization: Global tuberculosis control: surveillance, planning, financing. WHO report 2007. 2007, Geneva, World Health Organization"},{"key":"1215_CR14","volume-title":"Int J Tuberc Lung Dis","author":"SX Jittimanee","year":"2008","unstructured":"Jittimanee SX, Wiriyakitjar D, Jittimanee S, Nateniyom S, Kaophaithool S, Varma JK: Provider-initiated HIV testing and counseling in tuberculosis clinics in Thailand. Int J Tuberc Lung Dis. 2008"},{"key":"1215_CR15","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1046\/j.1537-2995.2003.00395.x","volume":"43","author":"N Nantachit","year":"2003","unstructured":"Nantachit N, Robison V, Wongthanee A, Kamtorn N, Suriyanon V, Nelson KE: Temporal trends in the prevalence of HIV and other transfusion-transmissible infections among blood donors in northern Thailand, 1990 through 2001. Transfusion. 2003, 43: 730-735. 10.1046\/j.1537-2995.2003.00395.x.","journal-title":"Transfusion"},{"key":"1215_CR16","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1111\/j.1365-3156.2006.01709.x","volume":"11","author":"V Chongsrisawat","year":"2006","unstructured":"Chongsrisawat V, Yoocharoen P, Theamboonlers A, Tharmaphornpilas P, Warinsathien P, Sinlaparatsamee S, Paupunwatana S, Chaiear K, Khwanjaipanich S, Poovorawan Y: Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop Med Int Health. 2006, 11: 1496-1502. 10.1111\/j.1365-3156.2006.01709.x.","journal-title":"Trop Med Int Health"},{"key":"1215_CR17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4269\/ajtmh.1997.57.66","volume":"57","author":"S Songsivilai","year":"1997","unstructured":"Songsivilai S, Jinathongthai S, Wongsena W, Tiangpitayakorn C, Dharakul T: High prevalence of hepatitis C infection among blood donors in northeastern Thailand. Am J Trop Med Hyg. 1997, 57: 66-69.","journal-title":"Am J Trop Med Hyg"},{"key":"1215_CR18","unstructured":"National TB program guidelines. 2005, Bangkok, TB Cluster, Bureau of AIDS, TB and STIs, Department of Diseases Control, Ministry of Public Health"},{"key":"1215_CR19","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1086\/512081","volume":"195","author":"A Neaigus","year":"2007","unstructured":"Neaigus A, Gyarmathy VA, Zhao M, Miller M, Friedman SR, Des Jarlais DC: Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users. J Infect Dis. 2007, 195: 1052-1061. 10.1086\/512081.","journal-title":"J Infect Dis"},{"key":"1215_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.drugalcdep.2007.01.003","volume":"89","author":"A Neaigus","year":"2007","unstructured":"Neaigus A, Gyarmathy VA, Miller M, Frajzyngier V, Zhao M, Friedman SR, Des Jarlais DC: Injecting and sexual risk correlates of HBV and HCV seroprevalence among new drug injectors. Drug Alcohol Depend. 2007, 89: 234-243. 10.1016\/j.drugalcdep.2007.01.003.","journal-title":"Drug Alcohol Depend"},{"key":"1215_CR21","first-page":"844","volume":"55","author":"Centers for Disease Control and Prevention","year":"2006","unstructured":"Centers for Disease Control and Prevention: HIV prevalence among populations of men who have sex with men--Thailand, 2003 and 2005. MMWR Morb Mortal Wkly Rep. 2006, 55: 844-848.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1215_CR22","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1097\/QAD.0b013e32814e6b08","volume":"21","author":"CJ Hoffmann","year":"2007","unstructured":"Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, Fielding KL, Churchyard GJ, Chaisson RE, Grant AD: Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS. 2007, 21: 1301-1308. 10.1097\/QAD.0b013e32814e6b08.","journal-title":"AIDS"},{"key":"1215_CR23","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.3748\/wjg.v11.i16.2518","volume":"11","author":"L Pan","year":"2005","unstructured":"Pan L, Jia ZS, Chen L, Fu EQ, Li GY: Effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus. World J Gastroenterol. 2005, 11: 2518-2521.","journal-title":"World J Gastroenterol"},{"key":"1215_CR24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/14659890500420095","volume":"11","author":"W Kittikraisak","year":"2006","unstructured":"Kittikraisak W, Davidson PJ, Hahn JA, Lum PJ, Evans JL, Moss AR, Page-Shafer K: Incarceration among young injectors in San Francisco: associations with risk for hepatitis C virus infection. J Subst Use. 2006, 11: 271-281. 10.1080\/14659890500420095.","journal-title":"J Subst Use"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2458-8-245.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2458-8-245\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2458-8-245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2458-8-245.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T01:27:50Z","timestamp":1630459670000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/1471-2458-8-245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,18]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["1215"],"URL":"https:\/\/doi.org\/10.1186\/1471-2458-8-245","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,18]]},"assertion":[{"value":"7 May 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"245"}}